Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
  • Sodium Salicylate

abstract

  • Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (n=4) and ototoxicity (n=4). One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2011.10.023

PubMed ID

  • 22154022

Additional Document Info

start page

  • 570

end page

  • 4

volume

  • 36

number

  • 5